We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26 ...